NYSE: AGE - AgeX Therapeutics, Inc.

Rentabilität für sechs Monate: 0%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan AgeX Therapeutics, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen AgeX Therapeutics, Inc.

AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes and obesity; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as peripheral vascular disease and ischemic heart disease.

weitere details
Its lead small molecule drug-based therapeutic candidate for scarless wound repair in discovery is AGEX-iTR1547, a drug-based formulation; and lead biologic candidate for induced tissue regeneration is AGEX-iTR1550 (Renelon), a gene delivery technology. AgeX Therapeutics, Inc. has a research collaboration with the University of California at Irvine to develop cellular therapies to treat neurological disorders and diseases. The company was incorporated in 2017 and is based in Alameda, California.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2018-11-29
ISIN US00848H1086
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.agexinc.com
Цена ао 11.1
Preisänderung pro Tag: 0% (11.1)
Preisänderung pro Woche: 0% (11.1)
Preisänderung pro Monat: 0% (11.1)
Preisänderung über 3 Monate: 0% (11.1)
Preisänderung über sechs Monate: 0% (11.1)
Preisänderung pro Jahr: -50.27% (22.32)
Preisänderung über 3 Jahre: +1 508.7% (0.69)
Preisänderung über 5 Jahre: +692.86% (1.4)
Preisänderung seit Jahresbeginn: 0% (11.1)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 2.98 6
P/BV 0.079 10
P/E 0 0
EV/EBITDA -0.4521 0
Gesamt: 5.13

Effizienz

Name Bedeutung Grad
ROA, % -123.72 0
ROE, % -270.67 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.4441 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % -91.65 0
Rentabilität Ebitda, % -15.27 0
Rentabilität EPS, % 4028.55 10
Gesamt: 2.6
Weitere Details

Institutionen Volumen Aktie, %
Broadwood Capital, Inc. 2997156 7.9
Vanguard Group Inc 701755 1.85
Sigma Planning Corp 286425 0.75
Prescott General Partners LLC 185185 0.49
Bridgeway Capital Management, Inc. 144770 0.38
Geode Capital Management, LLC 140994 0.37
Blackrock Inc. 124301 0.33
Strategic Wealth Investment Group, LLC 97375 0.26
Creative Planning 70700 0.19
Northern Trust Corporation 31533 0.08

ETFAktie, %Rentabilität für das Jahr, %Dividenden, %
Sprott Uranium Miners ETF 0.42828 343.52 3.27507
Global X Uranium ETF 0.21695 7.84 1.74266
0.33175.682.51



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Ms. Eun-Jae Park CPA Chief Financial Officer 295.29k 1972 (53 Jahr)
Dr. Ivan Labat Chief Information Officer N/A
Ms. Judith Segall Secretary N/A 1953 (72 Jahr)

Adresse: United States, Alameda. CA, 1101 Marina Village Parkway - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.agexinc.com